The pharmaceutical network on August 1, the price of the raw material drug monopoly, 2 drug companies was punished by the national development and reform commission.
On July 31, the official website of the national development and reform commission (NDRC) released the news that new secco and handewey were punished by the law for the price of raw materials.
▍ high-priced sales active pharmaceutical ingredients, drug firms was sent off
The drug companies that were punished were: zhejiang xinsecco pharmaceutical co., LTD., tianjin handewei pharmaceutical co., LTD. Development and reform commission (NDRC) abuse of dominant market position, to its at unfairly high prices sales isoniazid API, and without good reason refuses to deal the case in accordance with the law to make the decision, fines for the two companies, a total of 443900 yuan.
The national development and reform commission, said: monopoly behavior in medical industry is domestic regulatory focus in recent years, the investigation of zhejiang new secco pharmaceutical co., LTD., tianjin han, pharmaceutical co., LTD. Price monopoly, is advantageous to the standard API market price behavior, maintaining the order of the market price and the establishment of drug procurement fair market environment.
Both companies have resumed normal prices and supply to pharmaceutical companies.
▍ monopoly raw materials, pharmaceutical retail price is the most high 21 times
The original drug, isoniazid, was invented in 1952 and is mainly used for tuberculosis treatment. Although some patients have developed resistance to tuberculosis, many doctors consider it an essential drug for TB treatment.
The price of its product "isoniazid tablets" skyrocketed!
The price of the "isoniazid tablets", originally priced at 3 to 4 yuan, was up 21 times. Take online drugstore prices as an example, Shanghai xinyi's "isoniazid tablets", with a retail price of 3.8 yuan/box (100 pieces) showing a lack of goods, in another online store, priced at 82 yuan. The price of the "isoniazid tablets" of one manufacturer in shanxi is around 25 yuan, which is also a full 6.
This is a classic case of turning cheap drugs into overpriced drugs, and the raw material monopoly is likely to be the culprit. However, as two drug companies were fined and the original drug returned to normal prices, the retail price of the preparation products could fall back.
▍ CRC subsidiary, a dozen leading one of the active pharmaceutical ingredients
According to public information, zhejiang xinsecco pharmaceutical co., ltd. was founded in 2003. Established by China resources pharmaceutical co., Ltd and Zhejiang NHU Company Ltd., it is a subsidiary of China resources group.
Its main products include valsartan, isoniazid, nicotinamide and more than a dozen pharmaceutical products, which are the main domestic manufacturers in each product.
Another pharmaceutical company, tianjin handewei pharmaceutical co., LTD. Was established on October 10, 2008. The main products are isoniazid, nicotinic acid, nicotinamide, iso-nicotinic acid, and annual production capacity of 1000 tons of raw materials.
▍ development and reform commission (NDRC) will continue to crackdown on API monopoly
On June 28th, the state development planning commission, the national development and reform commission, ministry of industry and other nine departments jointly issued on the reform to perfect the shortage of drug supply security mechanism of the implementation opinions ", said to crackdown on apis to bid up prices and monopoly, two penalty drug firms, a negative case.
Next, the NDRC said it would continue to strengthen the regulation of antitrust, in accordance with the law to stop all areas restrict competition behavior, serious illegal monopoly agreements, abuse of dominant market position behavior, safeguard fair competition order and the legitimate interests of the operator. |
